Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence

INTRODUCTION AND BACKGROUND: While recurrent glioblastoma patients are often treated with re-irradiation, there is limited data on the use of re-irradiation in the setting of bevacizumab (BEV), temozolomide (TMZ) re-challenge, or immune checkpoint inhibition (ICI). We describe target delineation in...

Descripción completa

Detalles Bibliográficos
Autores principales: Christ, Sebastian M., Youssef, Gilbert, Tanguturi, Shyam K., Cagney, Daniel, Shi, Diana, McFaline-Figueroa, J. Ricardo, Chukwueke, Ugonma, Lee, Eudocia Q., Hertler, Caroline, Andratschke, Nicolaus, Weller, Michael, Reardon, David A., Haas-Kogan, Daphne, Guckenberger, Matthias, Wen, Patrick Y., Rahman, Rifaquat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689476/
https://www.ncbi.nlm.nih.gov/pubmed/38046107
http://dx.doi.org/10.1016/j.ctro.2023.100697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689476/
https://www.ncbi.nlm.nih.gov/pubmed/38046107
http://dx.doi.org/10.1016/j.ctro.2023.100697

Ejemplares similares